Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

References

• Gallagher C J, Gregory W M, Jones A E, Stansfeld A G, Richards M A, DhaliwaI H S. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 2005; 23: 6394–6399
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–2642
   PubMed Web of Science ®Google Scholar
• Plosker G L, Figgitt D P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803–843
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein Z P, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694–704
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone – results of a prospective randomised study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology. J Clin Oncol 2007; 25: 1986–1992
   PubMed Web of Science ®Google Scholar
• Salles G, Foussard C, Mounier N, Morschhauser F, Doyen C, Lamy T, et al. Rituximab added to αIFN-CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomised trial in 359 patients. Blood (Suppl.) 2004:160
   Google Scholar
• Sacchi S, Federico M, Vitolo U, Boccoinini C, Vallisa D, Baldini L, et al. Clinical activity and safety of combination immunotherapy with IFN-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951–958
   PubMed Web of Science ®Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• Davis T A, Maloney D G, Grillo-López A J, White C A, Williams M E, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α2a. Clin Cancer Res 2000; 6: 2644–2652
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Gribben J G, Freedman A, Woo S D, Blake K, Shu R S, Freeman G, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280
   PubMed Web of Science ®Google Scholar
• Deane M, Norton J D. Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification. Br J Haematol 1990; 74: 251–256
   PubMed Web of Science ®Google Scholar
• Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen S L, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515–1525
   PubMed Web of Science ®Google Scholar
• Rohatiner A Z, Gregory W M, Peterson B, Borden E, Solal-Celignv P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S F, Cogliatti S B, Pichert G, Hummerjohann J, WaItzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416–4423
   PubMed Web of Science ®Google Scholar
• Piro L D, White C A, Grillo-López A J, Janakiraman N, Saven A, Beck T M, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655–661
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, Eftekhari P, Soubevran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera®). Cancer Treat Rev 2005; 31: 456–473
   PubMed Web of Science ®Google Scholar